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Variation in dermcidin expression in a range of primary human
tumours and in hypoxic/oxidatively stressed human cell lines
GD Stewart*,1,2,4, RJE Skipworth1,4, CJ Pennington3, AG Lowrie1, DAC Deans1, DR Edwards3, FK Habib2,
ACP Riddick2, KCH Fearon1 and JA Ross1
1Tissue Injury and Repair Group, Clinical and Surgical Sciences (Surgery), University of Edinburgh, Edinburgh EH16 4SB, UK; 2Prostate Research Group,
Western General Hospital, Edinburgh EH4 2XU, UK; 3School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK
Dermcidin acts as a survival factor in a variety of cancer cell lines under hypoxia or oxidative stress. The aim of this study was to
evaluate dermcidin expression in cell lines following simulation of tumour microenvironmental conditions and in a range of primary
tumours. Tumour tissues were collected from patients with oesophageal (28 samples), gastric (20), pancreatic (five), bile duct (one)
and prostatic (52) carcinomas as well as 30 benign tissue samples, for assessment of dermcidin mRNA levels using real-time PCR.
Dermcidin expression was assessed in prostatic and pancreatic cancer cell lines, with and without induction of hypoxia or oxidative
stress. Dermcidin mRNA expression was very low or absent in both unstressed and stressed prostate cell lines. None of the primary
prostate tissue, benign or malignant, expressed dermcidin mRNA. Only two (4%) of the gastro-oesophageal cancer samples
expressed moderate quantities of dermcidin mRNA. However, three (60%) of the pancreatic cancer samples and the single
cholangiocarcinoma specimen had moderate/high levels of dermcidin expression. Of the two pancreatic cancer cell lines, one
expressed dermcidin moderately but neither showed a response to hypoxia or oxidative stress. Expression of dermcidin in human
primary tumours appears highly variable and is not induced substantially by hypoxia/oxidative stress in cell line model systems. The
relationship of these findings to dermcidin protein levels and cell survival remains to be determined.
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We have previously documented that dermcidin (DCD) acts as a
survival factor in prostate cancer cells exposed to either hypoxia or
oxidative stress (Stewart et al, 2007), and hepatoma cell lines
subject to oxidative stress (Lowrie et al, 2006). Porter et al (2003)
determined that DCD expression in breast cancer cell lines was
associated with cancer cell growth and survival . As such, DCD has
been suggested as a candidate oncogene in breast cancer (Porter
et al, 2003). Cunningham et al (1998) studied the role of oxidative
stress in neuronal degeneration and identified a 30 amino acid
survival-promoting peptide, which they named Y-P30. The Y-P30
peptide was present in medium conditioned by human retino-
blastoma cells and a mouse hippocampal cell line exposed to
hydrogen peroxide. Y-P30 was subsequently identified as compri-
sing part of a 110 amino acid polypeptide which Cunningham et al,
(2002) named diffusible survival evasion peptide (DSEP). DSEP-
overexpressing neuronal cells were also found to have an increased
resistance to oxidative stress (Cunningham et al, 2002).
The DCD gene was identified on chromosome 12q13.1 and
encodes different proteins with divergent biological functions
(Schittek et al, 2001; Stewart et al, 2008). The protein products of
the 110 amino acid DCD polypeptide (Figure 1) include the 47
amino acid DCD-1 peptide (a skin antimicrobial) (Schittek et al,
2001) and the 30 amino acid proteolysis-inducing factor-core
peptide (PIF-CP) (Lowrie et al, 2006), the latter of which is
identical to Y-P30 (Cunningham et al, 1998). The DCD protein
(Schittek et al, 2001) is identical to human cachexia-associated
protein (HCAP) (Akerblom and Murry, 1998) and DSEP (Cunning-
ham et al, 2002). Furthermore, when glycosylated, PIF is reported
to behave as a factor in cancer cachexia (Todorov et al, 1996).
Control of expression and post-translational processing of the
various protein subunits of DCD has not yet been fully elucidated
(Figure 1).
As DCD appears to encode both putative tumour survival and
cachectic factors, it represents an important potential therapeutic
target in cancer patients. Thus, this study aimed to evaluate the
expression of DCD mRNA (as a surrogate of Y-P30/PIF-CP
expression) using quantitative real-time PCR in a range of primary
tumours. Specifically, DCD expression by primary tumours from
patients with gastro-oesophageal, pancreatic, bile duct, and
prostate cancer was analysed. Furthermore, DCD expression was
also assessed in normal or benign tissue from the prostate,
stomach, oesophagus, and pancreas. Prostate cancer represents the
first tumour in which DCD/HCAP was described whereas the
upper gastrointestinal cancer types are associated significantly
with the development of cancer cachexia (DeWys et al, 1980).
Finally, to determine if DCD expression is upregulated in response
to stressors found in the cancer microenvironment (Brown andRevised 7 May 2008; accepted 12 May 2008; published online 1 July 2008
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Wilson, 2004; Valko et al, 2006; Vaupel et al, 2007), we have
analysed changes in the expression of DCD mRNA in prostate and
pancreatic cell lines in vitro in response to hypoxia or oxidative stress.
MATERIALS AND METHODS
Cell lines
The following human cancer cell lines were used in these studies:
hormone-sensitive prostate cancer cell line LNCaP; hormone-
insensitive prostate cancer cell lines PC-3, DU145 (all obtained
from the European Collection of Cell Cultures, Porton Down, UK
(ECACC)) and PC-3M (kindly donated by Dr C Pettaway,
University of Texas, MD Anderson Cancer Center, Houston, TX,
USA); and pancreatic adenocarcinoma cell lines CFPAC (ECACC)
and MIA-Pa-Ca-2 (ECACC). Two or more cell lines were utilised
for each organ site to obtain corroborative results.
The prostate cell lines were cultured in RPMI-1640 medium
(Invitrogen, Paisley, UK). Pancreatic cancer cell lines were cultured
in Dulbecco’s modified Eagle’s medium (Invitrogen). Media were
supplemented with 10% fetal calf serum (FCS), 50 units ml1
penicillin, 50 mg ml1 streptomycin and 2 mmol glutamine (all
Invitrogen). Cells were grown in 75 cm2 flasks (Corning BV,
Schipol-Rijk, The Netherlands).
Transfection of cells with DCD cDNA for use as positive
control
A robust positive control for real-time PCR was created by stably
transfecting PC-3M cells with a DCD-expressing vector. Wang et al
(2003) demonstrated that the PC-3M cell line does not express
DCD mRNA and it was thus chosen as a suitable cell line to be
transfected with a pcDNA3.1þDCD vector. The pcDNA3.1þ
mammalian expression vector (Invitrogen) had full length DCD
cDNA directionally cloned into the multiple cloning site
using the EcoR-I and BamH-I restriction enzymes (Promega,
Southampton, UK). pcDNA3.1þDCD vector was stably trans-
fected into PC-3M cells using FuGENE-6 (Roche Applied Science,
Lewes, UK). Geneticin selection antibiotic (Invitrogen)
(600mg ml1) was used to select transfected cells and eventually
create stable transfectants. Sham transfected PC-3M cells were
created using an empty pcDNA3.1 vector as a control. A total of
300mg ml1 Geneticin was used to supplement medium of
transfected cells to maintain the transfected cells.
Induction of oxidative stress in cancer cell lines
Stock solutions of 30% hydrogen peroxide, menadione sodium
bisulphite and glucose/glucose oxidase (GO) (Sigma, Poole, UK)
were diluted in medium appropriate for the cell line to be stressed.
DCD/DSEP gene
Chromosome 12q13.1
Transcription and translation
Components of the
unprocessed DCD
protein (110 aa)
Post-translational
modification
Glycosylation
Proteolytic processing
(mechanism unknown)
Function         Muscle proteolysis(increased protein degradation,
    decreased protein synthesis)
   Cancer cell survival
Cancer cell proliferation
  Neuronal cell survival
Antimicrobial protein
Glycosylated PIF
30 aa PIF-core/Y-P30 peptide
30 aa PIF-core/Y-P30 peptide 13 aa propeptide
47 aa DCD-1 polypeptide
110 aa unprocessed dermcidin (DCD) protein
ATG (start codon)
EXON 1 EXON 2 EXON 3 EXON 4 EXON 5
TAG (stop codon)
19 aa signal peptide 47 aa dermicidin (DCD-1) polypeptide
Figure 1 Outline of the dermcidin gene and the processing of its protein products (aa¼ amino acids). For DCD amino acid sequences see (Lowrie et al,
2006). (First appeared in Curr Opin Clin Nutr Metab Care Vol 11(3), pp 208–213 (2008) reproduced with kind permission).
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Three different oxidative stress-inducing compounds were
employed to allow confirmation that oxidative stress, rather than
other mechanisms of the ROS generating agents were at play.
Dose–response experiments were perfomed to determine the
approptiate doses of the oxidative stress-inducing agents to stress
the cell lines but not induce global cell necrosis. To assess levels of
cell death following oxidative stress induction, cells were
harvested, washed and stained with propidium iodide as described
previously (Stewart et al, 2007). One millimole of hydrogen
peroxide, 50 mM menadione or 5 mU ml1 GO were chosen to
oxidatively stress the cancer cells, resulting in mean levels of cell
necrosis of 56.5, 62.5 and 30.9% respectively after 24 h exposure.
Cells were incubated with oxidative stress-inducing compounds
for 24 h prior to RNA isolation.
Hypoxia induction
To simulate the hypoxic conditions within a solid tumour in vivo,
cells were incubated for 48 h within a humidified hypoxia
incubator at 0.2% oxygen (pO2B1.5 mm Hg) using a PROOX 110
oxygen controller (BioSpherix Ltd, NY, USA) (Brown and Wilson,
2004; Vaupel et al, 2007). This level of hypoxia resulted in a mean
of 62.7% cell death after 48 h. RNA was then isolated and assessed
for DCD expression.
Clinical tissue samples
Prostate samples Samples of malignant and benign human
prostate tissue were obtained from the Partners in Cancer
Research Tissue Bank, held in the Department of Histopathology
at the Norfolk and Norwich University Hospital. Details of ethical
approval, procedures for obtaining informed patient consent,
tissue acquisition, and histopathological and molecular quality
control and validation have already been described (Riddick et al,
2003). Samples of malignant prostate tissue were collected from
patients undergoing radical prostatectomy or channel transure-
thral resection of the prostate, and non-malignant samples were
obtained from patients undergoing radical cystoprostatectomy for
transitional cell carcinoma of the bladder or transurethral
resection of the prostate for benign prostatic hyperplasia. In all
68 primary prostate specimens were obtained (Table 1). The
prostate samples were made up of: 16 benign prostatic hyperplasia
specimens, eight Gleason 6 samples, 31 Gleason 7 samples, three
Gleason 8 samples, six Gleason 9 samples and four Gleason 10
samples.
Oesophageal, gastric, and pancreatic cancer samples Patients with
a firm radiological or histological diagnosis of pancreatic or
gastro-oesophageal cancer were recruited from the surgical unit of
the Royal Infirmary of Edinburgh. Patients provided written
informed consent and the study received ethical permission from
the Lothian Research Ethics Committee. Tissue was obtained from
patients at the time of operation. For patients undergoing surgical
resection with curative intent, a section of tumour tissue was
dissected from fresh surgical specimens under the guidance of a
consultant pathologist. For patients undergoing palliative bypasses
for pancreatic cancer, core biopsies of tumour tissue were taken
intraoperatively. Control gastric and oesophageal biopsies were
collected from healthy volunteers undergoing endoscopic investi-
gation of gastrointestinal symptoms. A consultant pathologist
analysed tissue sections to confirm the presence of malignant cells
in the tumour samples and the absence of malignant cells within
the benign samples. Tissue samples were snap-frozen in liquid
nitrogen before storage at 801C until further analysis. Clinical
information was collected prospectively.
Tissue samples were obtained from 28 oesophageal cancers and
20 gastric cancers (Table 1). Additionally, there were 10 benign
control samples from patients having upper GI endoscopy for
investigation of non-neoplastic pathologies.
Eleven tissue samples from patients having resections of
pancreatic masses were collected. These samples included a range
of diseases (Table 1): pancreatic adenocarcinoma (five samples);
chronic pancreatitis (two samples); and one sample each of
cholangiocarcinoma, liposarcoma, adenoma, and cystadenoma.
RNA isolation
Total RNA was extracted from cell lines using the TRIzol method
according to the manufacturer’s instructions (Invitrogen). The
resulting total RNA was quantified using an Ultraspec 2000
spectrophotometer (Pharmacia Biotech, Cambridge, UK).
Total RNA from the prostate tissues was isolated by first
homogenising tissues in RNAzol (Biogenesis, Poole, UK) and then
Table 1 Levels of DCD expression in primary tissue and cell lines for each organ site
Dermcidin expression level
Number of samples Number of samples
Organ Benign Cancer Cell line
Sample type:
benign, cancer
or cell line
Very
high (%)
High
(%)
Moderate
(%)
Low/absent
(%)
Not detected/below
the limits of
detection (%)
Oesophagus 5a 28 0 Benign: 0 0 0 0 5 (100)
Cancer: 0 0 0 4 (14.3) 24 (85.7)
Stomach 5a 20 0 Benign: 0 0 0 0 5 (100)
Cancer: 0 0 2 (10) 3 (15) 15 (75)
Pancreas 2b 5 2 Benign: 0 0 0 0 2 (100)
Cancer: 0 2 (40) 1 (20) 0 2 (40)
Cell Line: 0 0 1 (50) 1 (50) 0
Bile duct 0 1 0 Cancer: 0 1 (100) 0 0 0
Prostate 16c 52 4 Benign: 0 0 0 0 16 (100)
Cancer: 0 0 0 0 52 (100)
Cell Line: 0 0 0 3 (75) 1 (25)
Others 2d 1e 0 Benign: 0 0 0 0 2 (100)
Cancer: 0 0 0 1 (100) 0
aBenign samples taken during normal upper gastrointestinal endoscopy examinations. bChronic pancreatitis samples. cBenign prostatic hypertrophy samples. dPancreatic
liposarcoma and adenoma. ePancreatic cystadenoma.
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by using the Promega SV Total RNA Isolation System (Promega)
to remove DNA and purify the RNA. RNA was resuspended in
nuclease-free water and concentrations determined using a Nanodrop
spectrophotometer (LabTech International, Ringmoor, UK).
For RNA preparation from intact gastro-oesophageal and
pancreatic tissue samples a rotor –stator homogeniser was used
for homogenisation. RNA was then extracted using an RNeasy
kit (Qiagen, Crawley, UK) according to the manufacturer’s
instructions.
Real-time PCR
cDNA preparation and real-time PCR were performed as
previously described (Nuttall et al, 2003; Riddick et al, 2005).
Briefly, 1 mg of total RNA was reverse transcribed using 2 mg
random hexamers (Amersham, Little Chalfont, UK) and
Superscript II reverse transcriptase (Life Technologies, Paisley,
UK) according to the supplier’s instructions. cDNA was stored at
201C until used in the PCR.
For PCRs, specific primers and fluorogenic probes for DCD were
designed using Primer Express 1.0 software (Applied Biosystems,
Warrington, UK) and synthesised by Applied Biosystems. Figure 2
shows the primer and probes targets on the DCD nucleotide
sequence which partially overlaps with the nucleotide sequence for
the PIF-core peptide:
DCD real-time forward primer: CAAAAGGAAAATGCAGGT
GAAGA
DCD real-time reverse primer: TGGAAAAAGGCCTAGACGGAG
DCD real-time probe: FAM-ACAGGCACCAAAGCCAAGGAAG
CA-TAMRA
To control against amplification of genomic DNA, primers were
designed to span exon boundaries to control for genomic
amplification. The 18S rRNA gene was used as an endogenous
control to normalise for differences in the amount of total RNA in
each sample. 18S rRNA primers and probe were purchased from
Applied Biosystems. PCRs were performed using the ABI Prism
7500 fast Sequence Detection System (Applied Biosystems), using
the manufacturer’s protocol. Each reaction was performed in 25 ml
and contained the equivalent of 5 ng of reverse transcribed RNA
(1 ng RNA for the 18S analyses), 50% TaqMan 2 PCR Master
Mix (Applied Biosystems), 200 nM each of the forward and reverse
primer, and 100 nM of probe. Conditions for the PCR were 2 min at
501C, 10 min at 951C and then 40 cycles, each consisting of 15 s at
951C, and 1 min at 601C. The ABI Prism 7500 measured the cycle–
cycle changes in fluorescence in each sample and generated a
kinetic profile of DNA amplification over the 40-cycle PCR. The
cycle number (termed cycle threshold, or CT) at which amplifica-
tion entered the exponential phase was determined and this
number was used as an indicator of the amount of target RNA in
each tissue, that is, a lower CT indicated a higher quantity of
starting RNA. Relative standard curves for CT vs input RNA were
prepared, and relative levels of starting RNA in each sample were
determined. The relative standard curve method was used to
determine the fold change in gene expression between treated and
untreated cells. Only DNA samples with an 18S CT value within 1.5
CTs of the median CT for 18S were used for analysis as this value
suggested that the RNA was of sufficient quality for analysis of
DCD expression. We used the CT value of DCD to classify its
expression as: very high (CTo25.5), high (X25.5 CTo30.5),
moderate (X30.5 CTo35.5), low/absent (X35.5 CTo40), or not
detected/below the limits of detection (CT¼ 40) (Nuttall et al,
2003). Owing to a drop off in sensitivity of the instrument, CT
values X35.5 are unreliable, in terms of exact levels of mRNA
expression or assessing changes in CT values.
The DCD-transfected PC-3M cells transfected with the
pcDNA3.1þDCD plasmid gave a CT value of 23.1. Thus, the
positive control was in the very high range of DCD mRNA
expression.
Data analysis
All in vitro experiments were performed in sextuplet and repeated
three times. Where appropriate, values were expressed as means.
RESULTS
Dermcidin expression levels in prostate cancer cell lines
and clinical tissue samples
Prostate cancer cell lines with or without induction of oxidative
stress/hypoxia Prostate cancer cell lines demonstrated low or
absent levels of DCD expression. PC-3 had a CT value of 36.7,
LNCaP a CT of 39.2 and DU145 a CT of 39.6. PC-3M had a CT value
of 40.
Each of the prostate cancer cell lines was stressed with a variety
of oxidative stress-inducing agents or incubation under hypoxic
conditions. Dermcidin mRNA expression was marginally altered in
LNCaP cells when exposed to GO (2.4-fold increase ±1.7) or
menadione (2.3-fold increase ±1.2), in DU145 cells when exposed
to 0.2% hypoxia (1.7-fold increase ±1.1), and increased in PC-3M
cells following hypoxia and treatment with all three oxidative
stress-inducing compounds. Dermcidin expression by the PC-3
cell line was not elevated by any of the forms of stress utilised.
In all cases DCD expression failed to reach a level of expression
above an unreliable low/absent level (CT value X35.5) following
exposure to oxidative stress or hypoxia.
Primary prostate specimens None of the 68 primary prostate
samples, either benign or malignant, expressed dermcidin, all
having CT-values of 40 (Table 1).
Dermcidin expression levels in oesophageal and gastric
specimens
Table 1 details the DCD expression level of the gastric and
oesophageal samples. Nine (19%) of the 48 gastro-oesophageal
tumour samples displayed detectable levels of DCD expression
(CTo40), including four (14%) of the oesophageal cancers and five
(25%) of the gastric cancers. Only two (4%) of the cancer RNA
samples produced a DCD CT value o35.5, representing reliable
moderate levels of DCD expression (two gastric adenocarcinomas
Figure 2 Dermcidin nucleotide sequence. m denotes site of an intron. DCD real-time PCR primer target singly underlined and probe target doubly
underlined. PIF-core peptide nucleotide sequence in bold. Start and stop codons are shown in upper case.
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with CT values of 30.5 and 31.7 respectively). None of the 10 benign
control samples demonstrated detectable levels of DCD mRNA.
Dermcidin expression levels of pancreatic cell lines and
resection specimens
Pancreatic cancer cell lines with or without induction of oxidative
stress/hypoxia Both pancreatic cancer cell lines used in this study
demonstrated DCD mRNA expression. MIA-Pa-Ca-2 and CFPAC
cell lines had CT values of 35.1 and 37.6, moderate and low/absent
levels of DCD mRNA expression respectively.
Both MIA-Pa-Ca-2 and CFPAC cell lines were subjected to three
oxidative stress-inducing agents or incubation under hypoxic
conditions. DCD mRNA expression was marginally altered in
CFPAC cells when exposed to 0.2% oxygen (2.0-fold increase
±4.1), but not following oxidative stress. There was no upregula-
tion of DCD expression by MIA-Pa-Ca-2 on exposure to hypoxia
or oxidative stress. Although, DCD expression by CFPAC cells was
marginally altered following hypoxia it failed to reach a reliable,
moderate level of expression.
Primary pancreatic mass resection samples The histopathology
and CT values of samples that expressed DCD mRNA are shown in
Table 2. Five samples (45.5%) expressed DCD mRNA, three of
which had CT values 25.5– 30.5 defined as high levels of expression
(Table 1): 2 metastatic pancreatic adenocarcinomas and one poorly
differentiated cholangiocarcinoma. One sample, a liposarcoma,
had an unreliable low/absent level of DCD expression. Overall,
three of the five pancreatic cancer RNA samples (60%) had high or
moderate levels of DCD expression.
DISCUSSION
The results of this study showed a wide range of DCD expression
between different primary cancer types, namely: prostate, gastric,
oesophageal, pancreatic, and bile duct cancer. DCD mRNA
expression was undetectable in the primary prostate cancer
samples. In contrast, 60% of primary pancreatic cancer samples
expressed significant quantities of DCD mRNA. Additionally, the
MIA-Pa-Ca-2 pancreatic cancer cell line was the only cell line
reliably expressing DCD mRNA. However, dermcidin expression
by prostatic or pancreatic cancer cell lines was not substantially
increased by induction of hypoxia or oxidative stress.
The present study included a large number of patient samples
from five tumour types, plus benign tissue from some of the
affected organs. However, there were no samples taken from
distant metastatic deposits, which have been shown to express high
levels of DCD in previous studies (Wang et al, 2003).
In this study absolute CT values were used to assess DCD mRNA
expression. Owing to a drop off in the sensitivity of the instrument,
CT values greater than 35.5 are unreliable in terms of the amount of
mRNA expressed. Furthermore, the comparison of CT values
X35.5 is not reliable as differences in CT may not represent real or
meaningful differences in mRNA present. In primary tumour
samples, which have a large degree of cellular heterogeneity, CT
values greater than 35.5 mRNA represent low expression. Such CT
values may reflect generally low expression or there may be a
subset of cells expressing an appreciable level of the mRNA.
However, in cell lines, where heterogeneity is not such an issue, a
CT value greater than 35.5 means that mRNA may be expressed
(or could be absent), but if it is expressed it is at a very low level on
a per cell basis.
The results from primary prostate tissue suggest that DCD was
not expressed by primary prostate cancer. Moreover, if DCD
was present in the immortalised prostate cancer cell lines used, it
was present at a very low level. Although cancer cell lines would be
expected to have a uniform cell population, heterogeneity may
exist. As such, it could be speculated that there may be low or
absent pan-cellular DCD expression with a small subset
of immortalised cancer cells expressing some DCD. Resolution of
this issue would require different methodology than that used in
the present study.
Other sources suggest that DCD may well be expressed in
prostate cancer. In agreement with the data presented above, Wang
et al (2003) demonstrated DCD/HCAP mRNA expression in
prostate cancer cell lines other than PC-3M. However, Wang and
coworkers identified DCD/HCAP mRNA in primary prostate
cancers and bone metastasis specimens, results that differ from
those presented here. One possible explanation for these
differences is that Wang et al (2003) used RT–PCR rather than
real-time PCR.
A further hypothesis on the lack of DCD mRNA expression in
the prostate cancer samples analysed in the present study is
selective degradation of DCD mRNA. A major control in gene
expression is the turnover of mRNA, a tightly regulated process.
An important cis-acting element controlling the half-life of mRNA
are adenylate- and uridylate-rich (AU-rich) elements (AREs) found
in the 30 untranslated regions (UTRs) of many unstable mRNAs.
Adenylate-rich elements usually contain repeats of AUUUA,
inclusion of AUUUA motifs within 30UTRs of mRNA may
accelerate their decay. Dermcidin has one AUUUA pentamer
within its 30UTR (www.genomatix.de), which may make DCD
mRNA more susceptible to degradation. However, for destabilising
proteins to form stable complexes with ARE-containing mRNAs
many AUUUA pentamers are usually required (Bevilacqua et al,
2003).
Although induction of oxidative stress or hypoxia, two
conditions found in the tumour microenvironment, seemed to
result in an upregulation of DCD expression in several cancer cell
lines, the CT values remained in the low/absent range. As such,
oxidative stress and hypoxia failed to induce a substantial increase
in DCD mRNA expression by the pancreatic or prostatic cell lines
studied. However, the Y-P30 peptide subunit of DCD (Figure 1)
was originally purified from medium conditioned by human
retinoblastoma cells and a mouse hippocampal cell line exposed to
hydrogen peroxide (Cunningham et al, 1998). It was these findings
that stimulated the hypothesis for the present study, that is, that
DCD mRNA would be upregulated by the induction of oxidative
stress in prostatic and pancreatic cancer cell lines. It is not clear
why significant DCD upregulation following exposure to oxidative
stress (or hypoxia) did not occur in the present study. However,
there are several potential reasons that will form the basis of future
studies into DCD. Firstly, tiny concentrations (nanogram per
Table 2 Details of surgically resected pancreatic tumour pathology in
relation to DCD expression level
Pathology
WHO
stage
DCD CT
value
Level of
expression
Gall bladder metastasis from
pancreatic ductal
adenocarcinoma
IV 26.7 High
Metastatic pancreatic
adenocarcinoma
(liver metastasis)
IV 29.3 High
Pancreatic adenocarcinoma
(moderately differentiated)
IIa 30.9 Moderate
Cholangiocarcinoma (poorly
differentiated adenocarcinoma
with perineural and microvascular/
lymphatic invasion)
IVa 29.7 High
Liposarcoma N/A 35.6 Low/absent
WHO¼World Health Organisation; N/A¼ not applicable.
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millilitre) of DCD and its protein products have been shown to
cause biological effects (Cariuk et al, 1997; A Lowrie, unpublished
data) and as such improved methods of quantifying accurately
small changes in DCD expression caused by environmental
stressors, will be essential. Secondly, the stressors used in this
study may not have been suitable to cause DCD induction or
upregulation. Based on this premise, alternative inducers of
oxidative stress and induction of different tumour microenviron-
mental stresses (e.g., pH imbalance or nutrient deprivation) should
be evaluated. Finally, the DCD promoter region may simply not
have been induced to transcribe DCD by any of the stimuli used in
this study. As such, analysis of the DCD promoter region will be
required to progress the study of this interesting gene with
pleomorphic biological roles.
Assessment of 58 gastric and oesophageal biopsy samples
showed that DCD mRNA expression occurred in a small
percentage of gastro-oesophageal malignancy and that expression
levels were minimal. Only two gastro-oesophageal cancer RNA
samples (4%) expressed moderate DCD mRNA levels. The majority
of the gastric and oesophageal cancer patients were weight-losing.
Patients with DCD-expressing tumours did not have a significantly
greater weight loss, lower BMI or higher CRP than those patients
not expressing DCD (data not shown). However, with such low
numbers of DCD-expressing tumours, it was difficult to make
robust conclusions regarding differences in patient characteristics
between groups. Some of the samples utilised in this study had
been included in previous work from our laboratory (Deans et al,
2006). Deans et al (2006), found a higher percentage of PIF-CP
mRNA-expressing gastro-oesophageal samples than in the present
work. The previous analysis used the MIA-Pa-Ca-2 cell line as a
positive control from which to compare relative expression of DCD
mRNA. In the present study, MIA-Pa-Ca-2 was found to have a CT
value of 35.1, equating to borderline moderate DCD expression. As
such, we elected not to use MIA-Pa-Ca-2 as a positive control.
Thus, PIF-CP expression may have been overestimated in our
previous work because of comparison with a control, which has a
borderline moderate level of DCD mRNA expression. In the
current study, mRNA from PC-3M cells stably transfected with
DCD were used as a positive control for DCD real-time PCR.
However, as DCD had been artificially overexpressed in the PC-3M
cell line this was not an acceptable positive control for use in a
relative gene expression method of real-time data expression, as it
does not bear any relationship to the in vivo situation. Thus CT
values and DCD/18S rRNA ratios were used in this study to assess
DCD mRNA expression.
In the current study, the presence of DCD was assessed using
mRNA rather than protein levels. A DCD monoclonal antibody
called G-81 is available. However, G-81 recognises the C terminus
of DCD-1 rather than full length DCD or PIF-CP/Y-P30 (Minami
et al, 2004). Polyclonal antibodies to DCD also exist but we have
been unable to use these to identify successfully DCD or PIF-CP.
PIF is also reported to exist in a glycosylated form and is a putative
factor in the increased muscle proteolysis/decreased protein
synthesis of cancer cachexia (Lorite et al, 1997; Stewart et al,
2008). As the existing monoclonal antibody directed against PIF is
not specific to glycosylated PIF alone but may recognise a
carbohydrate epitope on other molecules, it was not used in the
present study (Wieland et al, 2007). As mentioned above, more
reliable and sensitive methods of quantifying DCD expression are
required. In particular a reliable assay for DCD protein estimation
is awaited and will be crucial to future studies.
Dermcidin and PIF-CP have been implicated in cancer cell
survival in a range of different types of cancer (Porter et al, 2003;
Lowrie et al, 2006; Stewart et al, 2007). The results presented here
demonstrate that DCD mRNA expression varies both between
tumour types and within primary tumours of the same type.
There was moderate expression of DCD in one of the pancreatic
cell lines but low/absent expression in all prostatic cancer cell
lines, findings that correlated with the overall DCD expression
patterns by the respective primary cancer tissues. Moreover, in
human cell lines where DCD was either not expressed or present
in small amounts, microenvironmental stress could not be proven
to induce or alter levels of DCD expression. The substantial
variability of DCD expression in primary tumours and cell
lines and lack of reliable methods of DCD induction in vitro
may require development of new model systems (perhaps based
on the MIA-Pa-Ca-2 cell line) and novel detection methods
for the DCD protein itself. These factors make the evaluation of
the role of DCD in human tumour biology elusive. As such, the
role of DCD expression between different tumour types and within
the same tumour type is difficult to ascertain. However, even low
levels of DCD expression by a subset of cancer cells may be
sufficient to promote clonal cancer cell survival in an adverse
environment. All previous studies assessing the various putative
roles of DCD and its subunits have involved in vitro techniques.
However, cell line models have limitations and the true role of
DCD in vivo remains to be fully elucidated. This study has
established that DCD seems to have most relevance to
bilio-pancreatic tumours. As such, further studies of DCD
expression in human pancreatic cancer and the relationship with
patient phenotype and outcome may be the optimum way of taking
the biology of human DCD forward.
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